首页> 外文期刊>Radiation oncology >Comparison of 3D anatomical dose verification and 2D phantom dose verification of IMRT/VMAT treatments for nasopharyngeal carcinoma
【24h】

Comparison of 3D anatomical dose verification and 2D phantom dose verification of IMRT/VMAT treatments for nasopharyngeal carcinoma

机译:3D解剖剂量验证及2D幻像剂量验证IMRT / VMAT治疗鼻咽癌的比较

获取原文
       

摘要

Background The two-dimensional phantom dose verification (2D-PDV) using hybrid plan and planar dose measurement has been widely used for IMRT treatment QA. Due to the lack of information about the correlations between the verification results and the anatomical structure of patients, it is inadequate in clinical evaluation. A three-dimensional anatomical dose verification (3D-ADV) method was used in this study to evaluate the IMRT/VMAT treatment delivery for nasopharyngeal carcinoma and comparison with 2D-PDV was analyzed. Methods Twenty nasopharyngeal carcinoma (NPC) patients treated with IMRT/VMAT were recruited in the study. A 2D ion-chamber array was used for the 2D-PDV in both single-gantry-angle composite (SGAC) and multi-gantry-angle composite (MGAC) verifications. Differences in the gamma pass rate between the 2 verification methods were assessed. Based on measurement of irradiation dose fluence, the 3D dose distribution was reconstructed for 3D-ADV in the above cases. The reconstructed dose homogeneity index (HI), conformity index (CI) of the planning target volume (PTV) were calculated. Gamma pass rate and deviations in the dose-volume histogram (DVH) of each PTV and organ at risk (OAR) were analyzed. Results In 2D-PDV, the gamma pass rate (3%, 3 mm) of SGAC (99.55%?±?0.83%) was significantly higher than that of MGAC (92.41%?±?7.19%). In 3D-ADV, the gamma pass rates (3%, 3 mm) were 99.75%?±?0.21% in global, 83.82%?±?16.98% to 93.71%?±?6.22% in the PTVs and 45.12%?±?32.78% to 98.08%?±?2.29% in the OARs. The maximum HI increment in PTVnx was 19.34%, while the maximum CI decrement in PTV1 and PTV2 were -32.45% and -6.93%, respectively. Deviations in dose volume of PTVs were all within ±5%. D2% of the brainstem, spinal cord, left/right optic nerves, and the mean doses to the left/right parotid glands maximally increased by 3.5%, 6.03%, 31.13%/26.90% and 4.78%/4.54%, respectively. Conclusion The 2D-PDV and global gamma pass rate might be insufficient to provide an accurate assessment for the complex NPC IMRT operation. In contrast, the 3D-ADV is superior in clinic-related quality assurance offering evaluation of organ specific pass rate and dose-volume deviations.
机译:背景技术使用杂交计划和平面剂量测量的二维幻像剂量验证(2D-PDV)已广泛用于IMRT治疗QA。由于缺乏关于验证结果与患者解剖结构之间的相关性的相关信息,临床评估中不充分。本研究中使用了三维解剖剂量验证(3D-ADV)方法,以评估鼻咽癌的IMRT / VMAT处理递送,并分析与2D-PDV的比较。方法在研究中招募了20例鼻咽癌(NPC)患有IMRT / VMAT治疗的患者。 2D离子室阵列用于单龙门角复合物(SGAC)和多功能架角复合物(MGAC)验证的2D-PDV。评估了2种验证方法之间的伽玛通过率的差异。基于测量辐照剂量注量,在上述情况下重建3D剂量分布3D-ADV。计算规划目标体积(PTV)的重建剂量均匀指数(HI),符合性指数(CI)。分析了每个PTV和器官的剂量直方图(DVH)的γ通过率和偏差(OAR)。结果在2D-PDV中,SGAC的γ流量(3%,3mm)(99.55%?±0.83%)显着高于MGAC(92.41%?±7.19%)。在3D-ADV中,GAMMA通过率(3%,3mm)为99.75%?±0.21%,在全球83.82%?±16.98%至93.71%?±6.22%,45.12%?±6.22% ?32.78%至98.08%?¼?2.29%在桨中。 PTVNX中的最大HI增量为19.34%,而PTV1和PTV2中的最大CI衰减分别为-32.45%和-6.93%。剂量体积的PTV偏差均在±5%以内。脑干,脊髓,左/右视神经的D2%,左/右腮腺的平均剂量最大程度地增加了3.5%,6.03%,31.13%/ 26.90%和4.78%/ 4.54%。结论2D-PDV和全球伽玛通率可能不足以为复杂的NPC IMRT操作提供准确的评估。相比之下,3D-ADV在临床相关的质量保证方面优越,提供了对器官特异性率和剂量偏差的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号